1616830-75-1

Upstream product

• 1616828-54-6 6-bromo-8-hydroxy-3H-quinazolin-4-one 
• 1616828-53-5 6-bromo-8-methoxy-3H-quinazolin-4-one 
• 1616828-84-2 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-8-((2-(trimethylsilyl)ethoxy)methoxy)-3-((2-(trimethylsilyl)ethoxy)methyl)quinazolin-4(3H)-one 
• 1616830-77-3 6-(3-(4-methylpiperazin-1-ylsulfonyl)phenyl)-8-((2-(trimethylsilyl)ethoxy)methoxy)-3-((2-(trimethylsilyl)ethoxy)methyl)quinazolin-4(3H)-one 
• 1215634-37-9 4-bromo-2-carboxy-6-methoxybenzenamine hydrobromide 
• 1616828-60-4 6-bromo-8-(2-trimethylsilanyl-ethoxymethoxy)-3-(2-trimethylsilanyl-ethoxymethyl)-3H-quinazolin-4-one 

Relevant academic research and scientific papers

COMT INHIBITORS

The present invention relates to compounds of formula (I), wherein the substituents are described in claim 1 and to the pharmaceutically acceptable salts thereof. These compounds inhibit the enzyme catechol-O-methyltransferase (COMT). The compounds may be used for the treatment of Parkinson's disease, depression, cognitive impairment and motor symptoms, resistant depression, cognitive impairment, mood and negative symptoms of schizophrenia.